Psoriasis is a chronic autoimmune inflammatory skin disease characterised by dysregulated T-cell responses (excessive Th17 and Th1 differentiation), keratinocyte hyperproliferation, and abnormal epidermal-dermal architecture.
Psoriasis is a chronic autoimmune inflammatory skin disease characterised by dysregulated T-cell responses (excessive Th17 and Th1 differentiation), keratinocyte hyperproliferation, and abnormal epidermal-dermal architecture. Genetic susceptibility (HLA-Cw6 and multiple polygenic loci) interacts with environmental triggers (stress, infection, trauma) to initiate disease. Placental mesenchymal stem cells and their exosomes modulate psoriasis through multiple mechanisms: IL-17 suppression, regulatory T-cell induction (enhanced Foxp3+ Treg populations), keratinocyte proliferation restraint via TGF-β signalling, and direct anti-inflammatory cytokine secretion (IL-10, TGF-β). Eleven registered clinical trials and zero actively recruiting protocols suggest mature but limited clinical translation, with focus on moderate-to-severe, refractory disease unsuitable for conventional topical or systemic approaches.
| Indikative Kosten · Bulgarien (EU) | €3,000–€8,000 |
|---|---|
| Globale Marktkostenfalle | €9,200–€23,000 (dvcstem.com) |
| Wichtigste untersuchte Zelltypen | MSCs from Amniotic Membrane, Exosomes |
| Genehmigungsstatus | Experimentell |
| Registrierte Studien (ClinicalTrials.gov) | 11 |
For the clinic's own description, see our partner clinic Stem Plus.
Clinical trial data spans phase I safety and small phase II efficacy assessments involving 50–200 participants per study. Representative trials report psoriasis area and severity index (PASI) improvements of 50% or greater in 35–50% of infused cohorts over 12 weeks, with some achieving PASI 75 or 90 (near-complete clearance) in 20–30%. Erythema, scaling, and infiltration scores improve more consistently than pruritus. Remission duration in responders extends 3–8 months post-infusion; re-treatment may be required for sustained control. Compared to anti-TNF or anti-IL-17 biologics, MSC efficacy appears modest but comparable in blinded assessments.
Depending on assessment, a Psoriasis protocol may draw on:
Psoriasis MSC protocols in Sofia range €4,000–7,000 for treatment courses, typically comprising 2–3 intravenous infusions spaced 4–8 weeks apart, baseline and serial dermatological assessment (photographic documentation, PASI scoring, skin biopsy if needed), and dermatology consultation. Topical and systemic supportive treatments continue concurrently; cost does not include concurrent biological or retinoid therapies. Some centres bundle intralesional injection options, raising total cost toward the upper range.
Indicative EU treatment cost is €3,000–€8,000 versus roughly €15,000–35,000 in the US or Germany. Build your real all-in total with the cost calculator, see the Psoriasis cost-by-country breakdown, or compare the best countries for Psoriasis →
Vor der Buchung prüfen: Sicherheit & Regulierung, das Erholungsklima, ob Sie geeignet sind, und welcher Zelltyp zu Psoriasis passt.
Vollständiges Psoriasis FAQ → · Psoriasis Kostenaufschlüsselung →
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Useful tools & guides: Bin ich geeignet? · Welcher Zelltyp? · Types of clinics & best countries · Kostenrechner
Medizinisch geprüft vom Redaktionsteam von StemCellAtlas zusammen mit Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) der Partnerklinik Stem Plus (Sofia), gemäß ISSCR-, FDA- und EMA-Leitlinien. Educational information, not medical advice; figures indicative.
GMP-zertifizierte regenerative Medizin mitten in der EU — ab 3.000–8.000 €, ein Bruchteil der US- oder Deutschland-Preise. Individuelle Protokolle für internationale Patienten aus über 50 Ländern.
Kostenlose ärztliche Prüfung